share_log

Baird Initiates Coverage On ResMed With Outperform Rating, Announces Price Target of $280

Baird Initiates Coverage On ResMed With Outperform Rating, Announces Price Target of $280

Baird開始對瑞思邁進行覆蓋,給予表現評級,宣佈目標股價爲280美元
Benzinga ·  09/24 18:26  · 評級/大行評級

Baird analyst Joe Vruwink initiates coverage on ResMed (NYSE:RMD) with a Outperform rating and announces Price Target of $280.

Baird 分析師Joe Vruwink 股票分析上瑞思邁(紐交所:RMD), 給予跑贏市場評級並宣佈目標股價爲280美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論